



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jacques P. Dumas, et al.

Group Art Unit: 1624

Serial No.: 09/636,519

Examiner: V. Balasubramanian

Filed: 08/10/2000

For: Substituted Pyridazines and Fused Pyridazines with Angiogenesis Inhibiting Activity

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 4, 2005

Signature of person certify

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>ISSUE FEE</u> TRANSMITTAL LETTER

Sir:

Enclosed please find the following documents in connection with transmittal and payment of the issue fee in the above-identified case:

- Part B Fee(s) Transmittal (Form PTOL-85B) [IN DUPLICATE];
- Amendment under 37 C.F.R. 1.312; and
- Return Receipt Post Card.

Respectfully submitted,

Date: January 4, 2005

William F. Gray

Attorney for Applicants

Reg. No. 31,018

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175 Telephone: (203) 812-2712 Facsimile: (203) 812-6459